AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05248620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin Clavulanic 500/125mg or placebo
Description: Prophylactic antibiotic treatment
Study NCT05001113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the subxiphoid approach thoracoscopic thymectomy
Description: A 2-cm straight incision was made in the middle of the xiphoid process, the incision was used as a thoracoscope hole, and the xiphoid process could be removed if necessary. The surgeon used the oval forceps to release the left and right soft tissue gaps behind the sternum, from the anterior mediastinum tunnel. Two 0.5 cm extrapleural thoracic ports under the bilateral costal arches were created, and this incision was used as an operation hole. The thread puncture cone with a diameter of 0.5 cm was placed under the guidance of the finger.
Study NCT05001113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the lateral intercostal approach thoracoscopic thymectomy
Description: Right-side approach: Use the left supine position. The observing port was created at the right axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.~Left-side approach: Use the right supine position. The observing port was created at the left axillary midline line in the fourth intercostal space, and the other two ports were made as to the operation hole along the anterior axillary lines in the third and fifth intercostal spaces.
Study NCT04945837 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: self administered questionnaire
Description: longitunidal descriptive study
Study NCT05890742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: In ARM Phase Ib Control group, Sintilimab will be used twice, q3w.
Study NCT05890742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310&Sintilimab
Description: In ARM Phase Ib\&III Experimental group，IBI310\&Sintilimab will be used in first cycle, Sintilimab will be used in second cycle(q3w). Radical surgery after neoadjuvant therapy.
Study NCT05890742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical surgery
Description: In ARM Phase Ib\&III Experimental group, Phase Ib Control group, subjects will receive radical surgery after neoadjuvant therapy. In ARM Phase III Control group,subjects will receive radical surgery without neoadjuvant therapy
Study NCT05355090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PP
Description: Protein Pacing three times per day
Study NCT05941377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood pressure lowering
Description: For EBPL group, patients are required to keep blood pressure at 100-120 mmHg. For SBPL group, patients are required to keep blood pressure at 120-140 mmHg.
Study NCT06245577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interdisciplinary mesh sacro colpopexy with resection rectopexy
Description: surgical reconstruction of the middel pelvic compartment with the above mentioned meshes combined with a resection rectopexy in a simultaneous interdisciplinary procedure
Study NCT06245577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: interdisciplinary mesh sacro colpopexy with resection rectopexy
Description: surgical reconstruction of the middel pelvic compartment with the above mentioned meshes combined with a resection rectopexy in a simultaneous interdisciplinary procedure
Study NCT04661670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: occlusal stabilization splints
Description: an intraoral appliance that has flat surface to allow bilateral posterior contacts in coincidence with physiologic condylar seating and to produce smooth anterior guidance in excursions
Study NCT05890742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: In ARM Phase Ib\&III Experimental group, Phase Ib Control group, subjects will receive radical surgery after neoadjuvant therapy. In ARM Phase III Control group,subjects will receive radical surgery without neoadjuvant therapy
Study NCT05592951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Crystal Light (once serving)
Description: Citric Acid, Potassium Citrate, Sodium Citrate, Aspartame (Phenylketonurics: Contains Phenylalanine), Magnesium Oxide, Maltodextrin, Contains Less than 2% of Natural Flavor, Acesulfame Potassium, Soy Lecithin, Yellow 5, Artificial Color.
Study NCT05592951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV with amino acids (one serving)
Description: Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
Study NCT05592951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV with amino acids (two servings)
Description: Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
Study NCT05592951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV with amino acids (three servings)
Description: Allulose, L-Alanine, L-Glutamine, Citric Acid, Sodium chloride, Lemon Lime Flavorings, Potassium Citrate, Trisodium Citrate Dihydrate, Dipotassium Phosphate, Syloid Silicon Dioxide, Stevia, Vitamin C, Vitamin B3, Calcium Pantothenate B5 (Vitamin B5), Vitamin B6, Vitamin B12. Liquid IV packets contain: sodium and potassium.
Study NCT04849923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training session
Description: Conduct of an 8-week strength training intervention of key muscle-tendon groups associated with knee joint stability in the training-specific setting of each participant. Participants are randomly allocated into three study groups with increasing levels of loading (Group#1: no training, Group#2: 1 training per week, Group#3: 3 trainings per week) with the same number of subjects and gender distribution in each group (n=12 per group, 6F and 6M). The same guidelines for the warm-up and the type of exercises will be given prior to the intervention study to each participant. Participants are asked to record exercise load and volume as well as monitor training-related variables and 1RM using the iOS Strength Control app. Participants perform the strength training self-directedly in their chosen fitness/training facilities as it fits into their weekly routine. Contact to the study investigator is ensured at all times in case of questions.
Study NCT04317638 — intervention group
Intervention type: OTHER
Intervention: Lipid profile
Description: 3 ml of venous blood from the breastfed and infants and mothers of the breastfed and mixed fed infants will be taken under aseptic precautions for determination of triglycerides (TG), cholesterol, high density lipoprotein (HDL), very low density lipoprotein (LDL) at the age of 14 ± 2 weeks and the age of 6 months.
Study NCT06256549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: Titrated to low dose or middle or high dose
Study NCT06256549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Titrated to 1.0 mg once a week
Study NCT05377294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Method of Levels therapy
Description: MOL therapy aims to help people develop awareness of their personal goals so they can identify incompatibilities and find potential solutions. In MOL, the therapist uses a specific style to help people focus attention on the problem at hand, long enough to consider the issues from different perspectives, including reflection on the associated emotions. This process is usually very experiential and requires the client to be actively engaged in controlling the focus of the session and decision making.
Study NCT04735887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SADL-eM
Description: The SADL-eM includes three elements essential to the intervention, namely: knowledge, skills, and advice. The manual includes 92 A5 pages with six detailed sections: an Introduction and five chapters: (1) Rehabilitation team, (2) Activities of Daily Living, (3) Assistive devices, (4) Home environment adaptation, and (5) Knowledge guide. The SADL-eM uses text and illustrative pictures that are carefully selected for contextual relevance. The manual is simple, easy, and suitable for people with a non-medical background.
Study NCT05586646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alanyl-glutamine
Description: Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
Study NCT04602585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education
Description: Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics
Study NCT04602585 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psycho-education
Description: Participants will receive 6 psycho-education sessions as adjunct therapy to the use of antipsychotics
Study NCT05882188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oil-based contrast
Description: oil-based contrast fluid, Lipiodol Ultra Fluid. Lipiodol is a solution of iodinated ethyl esters of fatty acids of poppyseed oil. Equivalent to 480 mg iodine per ml. The maximum dosage is 15ml. Lipiodol is produced by Guerbet, France. Lipiodol is FDA approved and registered as contrast agent for HSG.
Study NCT05882188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ExEm Foam
Description: ExEm Foam which is created by mixing 5ml ExEm-gel and 5ml of purified water. ExEm-gel contains hydroxyethylcellulose and glycerol. The ExEm Foam is distributed by IQ Medical Ventures, the Netherlands. ExEm Foam is FDA approved, CE marked and registered as contrast agent for HyFoSy.
Study NCT05186285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM338
Description: CM338 : a humanized monoclonal antibody.
Study NCT05186285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo.
Study NCT05570877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChitoCare medical Wound Healing Gel
Description: ChitoCare medical Wound Healing Gel is a CE-marked medical device.
Study NCT06557317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Girls for Wellness In-Person
Description: Weekly for 12 weeks, adolescent/caregiver dyads will attend 1) an in-person Wellness Session (mindfulness, nutrition lesson, dance class, program reflection) (90 min/wk) and 2) a home cooking experience using ingredients provided at the Wellness Session (60 min/wk).
Study NCT05839587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic TAPP
Description: Robotic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of docking of the robot and port placement and part 4 consists of de-docking and skin closure
Study NCT05839587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TAPP
Description: Laparoscopic TAPP consists of four different procedures. Part 2 and 3 will be the same for both procedures and will consist of hernia reduction and preparation of the preperitoneal space where the mesh is placed (part 2), mesh placement and suturing of the peritoneum (part 3). Part 1 consists of port placement only and part 4 consists of skin closure only.
Study NCT04383158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRGF ENDORET® obtained from ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16)
Description: ENDORET® POST-EXTRACTION ALVEOLUS DENTAL KIT (KMU16) is a system for obtaining plasma rich in growth factors (PRGF), which can be applied in the regeneration of bone and other connective tissues in oral surgery. PRGF is a completely autologous blood platelet concentrate that stimulates tissue regeneration due to enrichment with autologous growth factors, acting as a biological system.
Study NCT05024604 — intervention group
Intervention type: DRUG
Intervention: Progesterone Only Product in Oral Dose Form
Description: mini pills as a contraceptive method
Study NCT05024604 — intervention group
Intervention type: OTHER
Intervention: office hysterscopy
Description: office hysteroscoy
Study NCT05581966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DV-SSP Imaging
Description: DeepView utilizes imaging data from DFUs to aid in health care providers' assessment of wound healing potential. It is intended to be used as an aid to health care providers in the management of DFU wounds and not as a standalone prediction device.
Study NCT04955132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-learning
Description: The participants in the experimental arm will be able to use a food allergy e-learning tool, that provides comprehensive knowledge of the most common food allergies (milk, egg and wheat), their management and dietary guidelines.
Study NCT05096728 — intervention group
Intervention type: DRUG
Intervention: Nifedipine XL
Description: Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~* Once daily Nifedipine XL 60mg Vs.~* Twice daily Nifedipine XL 30mg
Study NCT04992910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation through medical device
Description: The patient will receive a therapy with functional electrical stimulation. For this, a device called Fesia Grasp will be used.~Duration: 80 min twice a week, for 6 weeks.
Study NCT04992910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Physical therapy applied to the subject. Duration: 80 min twice a week, for 6 weeks.
Study NCT04721392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental fatigue (Stroop task)
Description: A modified Stroop task of approximately 60 min will be used in order to induce mental fatigue (MF). This will be based on their performance during the max test that was conducted during the familiarization session. In this task, which will be partitioned in 4 blocks of 468 stimuli, four colored words (rood, blauw, groen and geel) will be presented one at a time on a computer screen. The participants will be required to indicate the color of the word, ignoring the meaning of the word itself.
Study NCT04721392 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (documentary)
Description: In the control task subjects will have to watch a documentary of 60 min on the same computer screen as the one used for the experimental trial. In order to avoid under- and over-arousal the subjects will have the opportunity to choose between several documentaries as proposed by the research team.
Study NCT03636165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: The local infiltration solution containing 1.25mg Methylprednisolone per milliliter.
Study NCT03636165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: The local infiltration solution containing 2mg Ropivacaine per milliliter.
Study NCT03636165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: The local infiltration solution containing 2mg Ropivacaine per milliliter.
Study NCT05238779 — intervention group
Intervention type: OTHER
Intervention: Standard of care including palliative care
Description: Usual care includes laboratory evaluations, imaging, and certain procedures and medications. In some cases of patients undergoing transplant evaluation, usual care will also include multiple visits with members of the liver transplant team. A palliative care consult will also be part of standard of care. The primary goal of the palliative care consult is not to arrange hospice (though that can be done in appropriate situations) but to identify and try to address the impacts of the disease and its symptoms on patient's life.
Study NCT05113290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Adenovirus Type 5 injection
Description: Intratumoral injection of lesions with dose of 3 vials (1.5 × 10\^12 vp) if the sum of the maximum lesion diameters was > 10 cm, 2 vials (1.0 × 10\^12 vp) if the sum of the maximum lesion diameters was ≤ 10 cm. The cycle is 21 days up to 2-5 cycles.
Study NCT05896761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injectable Suspension
Description: CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
Study NCT05113290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.
Study NCT05113290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be administered as the original dose before enrollment, or be adjusted by the doctor according to the tolerance.
Study NCT05896761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Injectable Suspension
Description: RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
Study NCT05384678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine (54 mg)
Description: A dose rate of 0.6 mg/min will be administered
Study NCT05384678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine (108 mg)
Description: A dose rate of 1.2 mg/min will be administered
Study NCT05384678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine (162 mg)
Description: A dose rate of 1.8 mg/min will be administered
Study NCT05384678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine (216 mg)
Description: A dose rate of 2.4 mg/min will be administered
Study NCT05939726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturising cream with vitamin E concentrate
Description: The vitamin E moisturising cream contains 3% w/w of palm-oil-derived vitamin E concentrate, consisting of the following isomers: alpha-tocopherol, alpha-tocotrienol, beta-tocotrienol, gamma-tocotrienol, and delta-tocotrienol. This formula provides a total of 1.2g tocotrienols per 100g product.
Study NCT05939726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturising cream without vitamin E concentrate
Description: This moisturising cream is a similar moisturising cream but without the addition of the vitamin E concentrate
Study NCT05939726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urea cream
Description: Urea cream (10%w/w) is used as the standard of care for PPE.
Study NCT05939726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urea cream
Description: Urea cream (10%w/w) is used as the standard of care for PPE.
Study NCT05377125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: This intervention offers 45-minute computerized training sessions to each participant. This intervention aims to improve the individual's RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
Study NCT05377125 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized placebo training
Description: This intervention offers 45-minute computerized placebo cognitive training sessions to each participant. This intervention aims to exert no focused training on RI capabilities. All participants will receive 8 to 16 sessions after being randomized to this condition.
Study NCT04660370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348
Description: QD, PO
Study NCT04660370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D097, D337
Description: QD, PO
Study NCT04767958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spartan COVID-19 Platform
Description: Nasal-pharyngeal swab for testing on the Spartan Covid-19 platform
Study NCT04639791 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observation only, no intervention
Study NCT05384678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A Placebo (saline infusion) will be administered.
Study NCT05478928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic dry needling
Description: An acupuncture needle of 0.3 x 25 mm will be introduced perpendicularly into the upper trapezius trigger point. A movement with the needle will be done at 1 Hz for 120 seconds.
Study NCT05478928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed dose dynamic MEP
Description: Cathodic low intensity percutaneous electrolysis will be applied through an acupuncture needle of 0.3 x 25 mm in the upper trapezius trigger point. A movement with the needle will be done at 1 Hz with an intensity of 600 micro-Amperes. If the patient refers discomfort, the procedure will be stopped and resumed totalling 120 seconds (total dose of 72 mC).